Performance of prostate health index and PSA density in a diverse biopsy-naïve cohort with mpMRI for detecting significant prostate cancer.
Samuel CarbunaruJames StinsonRilwan BabajideCourtney M P HollowellXiming YangMarin SekosanKaren FerrerAndre Kajdacsy-BallaJosephine AbelleiraMaria RudenPatrice King-LeeDaniel P DaltonDavid D CasalinoRick A KittlesPeter H GannEdward M SchaefferBernice OforiPublished in: BJUI compass (2021)
PHI and PSA density can be used after mpMRI to improve the detection of GG2-5 PCa in a biopsy-naïve cohort. PHI may be superior to PSA density in PIRADS 3 lesions by avoiding 55% of unnecessary biopsies. Using both PHI and PSA density in series may further increase specificity and lead to fewer unnecessary biopsies, but further larger studies are warranted to determine the optimal threshold of each biomarker.